{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:10:16Z","timestamp":1745035816088,"version":"3.40.4"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,4,17]]},"DOI":"10.1248\/bpb.b24-00766","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:12:41Z","timestamp":1744841561000},"page":"383-389","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Myocarditis Caused by Drugs Used for Ulcerative Colitis as Examined Using VigiBase, a Spontaneous Adverse Drug Reaction Reporting Database"],"prefix":"10.1248","volume":"48","author":[{"given":"Yumi","family":"Kawai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shujitsu University, 1\u20136\u20131 Nishigawara, Naka-ku, Okayama 703\u20138258, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, 3\u201318\u201315 Kuramoto-cho, Tokushima 770\u20138503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, 2\u201350\u20131 Kuramoto-cho, Tokushima 770\u20138503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, 3\u201318\u201315 Kuramoto-cho, Tokushima 770\u20138503, Japan"},{"name":"Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, 2\u201350\u20131 Kuramoto-cho, Tokushima 770\u20138503, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shujitsu University, 1\u20136\u20131 Nishigawara, Naka-ku, Okayama 703\u20138258, Japan"},{"name":"Department of Pharmacy, Okayama University Hospital, 2\u20135\u20131 Shikata-cho, Kita-ku, Okayama 700\u20138558, Japan"},{"name":"Department of Pharmacy, Okayama Kyokuto Hospital, 567\u20131 Kurata, Naka-ku, Okayama 703\u20138265, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"doi-asserted-by":"crossref","unstructured":"1) Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>J. Gastroenterol.<\/i>, <b>56<\/b>, 489\u2013526 (2021).","key":"1","DOI":"10.1007\/s00535-021-01784-1"},{"doi-asserted-by":"crossref","unstructured":"2) Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. <i>Lancet<\/i>, <b>390<\/b>, 2769\u20132778 (2017).","key":"2","DOI":"10.1016\/S0140-6736(17)32448-0"},{"unstructured":"3) Ministry of Health, Labour and Welfare, Japan. \u201cDiagnostic criteria and treatment guidelines for ulcerative colitis and Crohn\u2019s disease\u201d (2023): &lt;http:\/\/www.ibdjapan.org\/pdf\/doc15.pdf&gt;, accessed 17 October, 2023.","key":"3"},{"doi-asserted-by":"crossref","unstructured":"4) Nguyen HN, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analysis. <i>Lancet Gastroenterol. Hepatol.<\/i>, <b>3<\/b>, 742\u2013753 (2018).","key":"4","DOI":"10.1016\/S2468-1253(18)30231-0"},{"unstructured":"5) Takeda Pharm USA. Inc. \u201cLIALDA delayed-release tablets, 1.2 g: a medical package insert\u201d (2022): &lt;https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022000lbl.pdf&gt;, accessed 17 October, 2023.","key":"5"},{"doi-asserted-by":"crossref","unstructured":"6) Nagai T, Inomata T, Kohno T, et al. JCS 2023 guideline on the diagnosis and treatment of myocarditis. <i>Circ. J.<\/i>, <b>87<\/b>, 674\u2013754 (2023).","key":"6","DOI":"10.1253\/circj.CJ-22-0696"},{"doi-asserted-by":"crossref","unstructured":"7) Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, Ishizawa K. Factors associated with immune checkpoint inhibitor-related myocarditis. <i>JAMA Oncol.<\/i>, <b>5<\/b>, 1635\u20131637 (2019).","key":"7","DOI":"10.1001\/jamaoncol.2019.3113"},{"unstructured":"8) Koh Y, Nagaya T, Saegusa H, Ikeuchi H, Kodama R, Ushimaru H. Mesalazine-induced myocarditis. <i>Nihon Shokakibyo Gakkai Zasshi<\/i>, <b>117<\/b>, 1093\u20131099 (2020).","key":"8"},{"doi-asserted-by":"crossref","unstructured":"9) Liu M, Gu L, Zhang Y, Zhou H, Wang Y, Xu Z-X. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system. <i>Front. Pharmacol.<\/i>, <b>15<\/b>, 1290975 (2024).","key":"9","DOI":"10.3389\/fphar.2024.1290975"},{"unstructured":"10) Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Japan. \u201cReport of the examination results of LIALDA, 1,200 mg.\u201d (2016): &lt;https:\/\/www.pmda.go.jp\/drugs\/2016\/P20161021001\/790005000_22800AMX00689_A100_1.pdf&gt;, accessed 17 October, 2023.","key":"10"},{"doi-asserted-by":"crossref","unstructured":"11) Kubota K. Signal detection from spontaneous reports: new methods in MCA in the UK, FDA in the U.S. and WHO. <i>Jpn. J. Pharmacoepidemiol.<\/i>, <b>6<\/b>, 101\u2013108 (2001).","key":"11","DOI":"10.3820\/jjpe1996.6.101"},{"doi-asserted-by":"crossref","unstructured":"12) Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>54<\/b>, 315\u2013321 (1998).","key":"12","DOI":"10.1007\/s002280050466"},{"doi-asserted-by":"crossref","unstructured":"13) Ramdani Y, Largeau B, Jonville-Bera AP, Maillot F, Audemard-Verger A. COVID-19 vaccination as a trigger of IgA vasculitis: a global pharmacovigilance study. <i>J. Rheumatol.<\/i>, <b>50<\/b>, 564\u2013567 (2023).","key":"13","DOI":"10.3899\/jrheum.220629"},{"doi-asserted-by":"crossref","unstructured":"14) Xia S, Gong H, Wang YK, Liu L, Zhao YC, Guo L, Zhang BK, Sarangdhar M, Noguchi Y, Yan M. <i>Pneumocystis jirovecii<\/i> pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the FAERS database. <i>Front. Pharmacol.<\/i>, <b>14<\/b>, 1129730 (2023).","key":"14","DOI":"10.3389\/fphar.2023.1129730"},{"doi-asserted-by":"crossref","unstructured":"15) L\u00e9tinier L, Ferreira A, Marceron A, Babin M, Micallef J, Miremont-Salam\u00e9 G, Pariente A. Spontaneous reports of serious adverse drug reactions resulting from drug-drug interactions: an analysis from the French pharmacovigilance database. <i>Front. Pharmacol.<\/i>, <b>11<\/b>, 624562 (2021).","key":"15","DOI":"10.3389\/fphar.2020.624562"},{"doi-asserted-by":"crossref","unstructured":"16) Becker SA, Wishnitzer R, Botwin S, Eliraz A, Bass DD. Myopericarditis associated with inflammatory bowel disease. <i>J. Clin. Gastroenterol.<\/i>, <b>3<\/b>, 267\u2013270 (1981).","key":"16","DOI":"10.1097\/00004836-198109000-00011"},{"doi-asserted-by":"crossref","unstructured":"17) Noguchi Y, Yamashita S, Tamaki H, Osanai A, Ino Y, Tachi T, Iguchi K, Teramachi H. Signal detection study focusing on differences in the drug delivery system of oral 5-aminosalicylate for inflammatory bowel disease using the Japanese Pharmacovigilance Database. <i>Pharmacoepidemiology<\/i>, <b>2<\/b>, 26\u201334 (2023).","key":"17","DOI":"10.3390\/pharma2010003"},{"unstructured":"18) AYUMI Pharmaceutical Corporation. \u201cAzulfidine. <i>EN Tablets<\/i>, 250 mg and 500 mg: a medical package insert\u201d (2023): &lt;https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/172190_6219001H1056_3_03&gt;, accessed 18 October, 2023.","key":"18"},{"unstructured":"19) Mitsubishi Tanabe Pharma Corporation. \u201cAZANIN tablets, 50 mg: a medical package insert\u201d (2020): &lt;https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/670109_3999005F1040_2_01&gt;, accessed 18 October, 2023.","key":"19"},{"doi-asserted-by":"crossref","unstructured":"20) Matsushita I. Epidemiology, diagnosis and practice guidelines for rheumatoid arthritis. <i>Jpn. J. Rehabil. Med.<\/i>, <b>57<\/b>, 1005\u20131010 (2020).","key":"20","DOI":"10.2490\/jjrmc.57.1005"},{"unstructured":"21) Sigal LH, Friedman HD. Rheumatoid pancarditis in a patient with well controlled rheumatoid arthritis. <i>J. Rheumatol.<\/i>, <b>16<\/b>, 368\u2013373 (1989).","key":"21"},{"doi-asserted-by":"crossref","unstructured":"22) Amigues I, Tugcu A, Russo C, Giles JT, Morgenstein R, Zartoshti A, Schulze C, Flores R, Bokhari S, Bathon JM. Myocardial inflammation, measured using 18-fluorodeoxyglucose positron emission tomography with computed tomography, is associated with disease activity in rheumatoid arthritis. <i>Arthritis Rheumatol.<\/i>, <b>71<\/b>, 496\u2013506 (2019).","key":"22","DOI":"10.1002\/art.40771"},{"doi-asserted-by":"crossref","unstructured":"23) Shiohara T, Kano Y, Hirahara K, Aoyama Y. Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>13<\/b>, 701\u2013704 (2017).","key":"23","DOI":"10.1080\/17425255.2017.1297422"},{"doi-asserted-by":"crossref","unstructured":"24) Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS-associated myocarditis. <i>J. Am. Acad. Dermatol.<\/i>, <b>66<\/b>, e229\u2013e236 (2012).","key":"24","DOI":"10.1016\/j.jaad.2010.11.057"},{"doi-asserted-by":"crossref","unstructured":"25) Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. <i>Allergol. Int.<\/i>, <b>68<\/b>, 301\u2013308 (2019).","key":"25","DOI":"10.1016\/j.alit.2019.03.006"},{"unstructured":"26) Matsui T, Umetsu R, Kato Y, Ueda N, Abe J, Nakayama Y, Hane Y, Kinosada Y, Nakamura M. Adverse event signals of interstitial lung disease in the FDA Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. <i>Jpn J. Drug Inform.<\/i>, <b>17<\/b>, 145\u2013154 (2015).","key":"26"},{"doi-asserted-by":"crossref","unstructured":"27) Yoshimura K, Kadoyama K, Sakaeda T, Sugino Y, Ogawa O, Okuno Y. A survey of the FAERS database concerning the adverse event profiles of \u03b11-adrenoreceptor blockers for lower urinary tract symptoms. <i>Int. J. Med. Sci.<\/i>, <b>10<\/b>, 864\u2013869 (2013).","key":"27","DOI":"10.7150\/ijms.5892"},{"doi-asserted-by":"crossref","unstructured":"28) Poluzzi E, Raschi E, Moretti U, De Ponti FD. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiol. Drug Saf.<\/i>, <b>18<\/b>, 512\u2013518 (2009).","key":"28","DOI":"10.1002\/pds.1746"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00766\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T03:34:42Z","timestamp":1745033682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00766\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00766","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"b24-00766"}}